Is Bristol-Myers Squibb Stock Underperforming the Nasdaq?

Though Bristol-Myers Squibb has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain ...

Q4 Earnings Outperformers: Bristol-Myers Squibb (NYSE:BMY) And The Rest Of The Branded Pharmaceuticals Stocks

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Bristol-Myers Squibb (NYSE:BMY) and ...

Is Bristol Myers Squibb (BMY) Pricing Look Attractive After Recent Share Price Climb

If you are wondering whether Bristol-Myers Squibb is offering good value right now, this article will walk through what the ...
Zacks Investment Research on MSN

Merck vs. Bristol Myers: Which pharma stock is a better pick in 2026?

Merck & Co. MRK and Bristol Myers Squibb BMY are major global drugmakers with expansive, diversified portfolios. Merck stands out for its leadership in oncology, complemented by strong positions in ...
Zacks.com on MSN

Here is What to Know Beyond Why Chewy (CHWY) is a Trending Stock

Chewy (CHWY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past ...
Fintel on MSN

Barclays initiates coverage of Bristol-Myers Squibb (BMY) with overweight recommendation

Fintel reports that on February 20, 2026, Barclays initiated coverage of Bristol-Myers Squibb (NYSE:BMY) with a Overweight ...
sharewise

Can Reblozyl Stabilize BMY's Top Line Amid Legacy Drugs Decline?

Bristol Myers BMY is banking on its growth portfolio, which comprises Opdivo, Orencia, Yervoy, Reblozyl, Opdualag, Abecma, Zeposia, Breyanzi, Camzyos, Sotyku, Krazati and others, to drive top-line ...
Nasdaq

BMY Up 7.6% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock?

Bristol Myers Squibb BMY has strengthened its near-term outlook following robust fourth-quarter 2025 results reported on Feb. 5, 2026. The stock rose 7.6% post-earnings, closing at $61.99 on Feb. 6 — ...
Insider Monkey

Bristol-Myers Squibb Company (BMY) Growth Portfolio Driving Earnings Growth

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best long-term stocks to invest in for retirement. On February 10, Bernstein SocGen Group reiterated its Market Perform rating and $58 price ...
Insider Monkey

Guggenheim Raises its Price Target on Bristol-Myers Squibb Company (BMY) to $72 and Reiterates a Buy Rating

On February 6, 2026, Guggenheim raised its price target on Bristol-Myers Squibb Company (NYSE:BMY) to $72 from $62 and reiterated a Buy rating. The firm significantly increased its estimated ...

IHE: U.S. Pharmaceuticals ETF With Excellent GARP Features

IHE has an attractive mix of high-growth stocks and cheaply valued ones. Click here to find out why IHE stock is a Buy.

Vertex Pharmaceuticals Stock: Is The Bull Run Over (Rating Downgrade)

Vertex Pharmaceuticals Incorporated faces slowing Trikafta/Kaftrio sales and a stock-price divergence with peers. Click for this VRTX earnings update.